-
Mashup Score: 2
UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Elevated Fecal Calprotectin Linked to Often Unnecessary Colonoscopy in Pediatric H. Pylori, with Jessica Lat, MD - 11 hour(s) ago
HCPLive spoke with Lat at NASPGHAN 2024 about how for communities with high H. pylori prevalence, it is best to test for H. pylori before a colonoscopy.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Elevated fecal calprotectin often leads to unnecessary colonoscopies in children with H. pylori, Jessica Lat told HCPLive at #NASPGHAN2024. Check out the interview here: https://t.co/efkqXn571A
-
-
Mashup Score: 0
This analysis evaluated the frequency of peanut-sensitized infants and toddlers being sensitized to other types of nuts.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
A very high number of infants and toddlers who have been peanut-sensitized and live with #eczema are already co-sensitized to tree nuts, a new study suggests. https://t.co/swhg7n88F2
-
-
Mashup Score: 0
In these guidelines compiled by the ACAAI, the AAAAI, and the AAOA, recommendations are provided to insurance companies for documentation needed for allergen immunotherapy.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
The @AAAAI_org, the @ACAAI, and the @ENTAllergyDocs have released a set of guidelines to insurance companies concerning necessary requirements for allergen #immunotherapy documentation. To learn more, view our summary here 👇 https://t.co/f5K3JJgMvT
-
-
Mashup Score: 3
UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
🚨BREAKING🚨 The #FDA has approved bimekizumab (#Bimzelx) for the treatment of adults of moderate to severe hidradenitis suppurativa, also known as #HS. Want to learn more? View our summary here 👇 https://t.co/ZU6YyPDPKy
-
-
Mashup Score: 1American Association for the Study of Liver Diseases - 2 day(s) ago
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
A great weekend in Boston for #TLM23! Thanks to everyone who’s been a part of our coverage thus far, and stay tuned for plenty more interviews and reports this week: https://t.co/V9cpxh9Gb2 #hepatology #AASLD https://t.co/jVrKWUOjsy
-
-
Mashup Score: 0
In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
After the 2025 GOLD Report added revisions, MeiLan K. Han, MD, of @umichmedicine spoke in an interview about the updates for dupilumab/ensifentrine and their significance for patients with #COPD. Check out Dr. Han's new interview here 👇 https://t.co/0l4NNEDzZh
-
-
Mashup Score: 22Finding a Role for GLP-1 RAs, Incretin Therapies in Heart Failure, with Muthiah Vaduganathan, MD, MPH - 2 day(s) ago
Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
At #AHA24, we spoke with @Mvaduganathan about the role of GLP-1 receptor agonists and incretin therapies in heart failure, particularly obesity-related HFpEF. #HeartFailure https://t.co/l7IxZvaJu7
-
-
Mashup Score: 0
The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
"People [with Lupus] need to be on less steroids and feel better, and we managed to do that really nicely." - Dr. Megan Clowse @DukeMedSchool at #ACR24 on positive findings from the phase 3 PHOENYCS-GO trial of DZP + SOC. Read more: https://t.co/P189Vd4g62
-
-
Mashup Score: 0
In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet-
After the 2025 GOLD Report added revisions, MeiLan K. Han, MD, of @umichmedicine spoke in an interview about the updates for dupilumab/ensifentrine and their significance for patients with #COPD. Check out Dr. Han's new interview here 👇 https://t.co/0l4NNEDzZh
-
🚨BREAKING🚨 The #FDA has approved bimekizumab (#Bimzelx) for the treatment of adults of moderate to severe hidradenitis suppurativa, also known as #HS. Want to learn more? View our summary here 👇 https://t.co/ZU6YyPDPKy